Catalio Capital Management, LP — 13F Holdings & Portfolio
CIK 1958125 · latest 13F-HR filed 2026-08-14
Catalio Capital Management, LP manages $532.1M in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AVLN (10.37%), JNJ (6.63%), GILD (6.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 13; 20 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 56.7%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
5TH FLOOR
NEW YORK, NY 10011
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CATALIO CAPITAL GP, LLC Control | GENERAL PARTNER since Jun 2020 | Less than 5% | Domestic Entity |
| KKR CATALINA HOLDINGS L.P. Control | LIMITED PARTNER since Oct 2023 | 25–50% | Domestic Entity |
| STONEBIRD PARTNERS, LP Control | LIMITED PARTNER since Jan 2023 | 50–75% | Domestic Entity |
| MALTSEVA, OLGA, EDUARDOVNA | CHIEF COMPLIANCE OFFICER AND HEAD OF OPERATIONS since Jun 2021 | Less than 5% | Individual |
| KKR & CO. INC. Control Indirect owner via KKR GROUP CO. INC. | SHAREHOLDER since Oct 2023 | 75% or more | Domestic Entity |
| KKR CATALINA GP LLC Control Indirect owner via KKR CATALINA HOLDINGS L.P. | GENERAL PARTNER since Oct 2023 | General partner, trustee or manager | Domestic Entity |
| KKR GROUP ASSETS GP II LLC Control Indirect owner via KKR GROUP ASSETS HOLDINGS II L.P. | GENERAL PARTNER since Oct 2023 | General partner, trustee or manager | Domestic Entity |
| KKR GROUP ASSETS HOLDINGS II L.P. Control Indirect owner via KKR CATALINA GP LLC | SOLE MEMBER since Oct 2023 | 75% or more | Domestic Entity |
| KKR GROUP ASSETS HOLDINGS II L.P. Control Indirect owner via KKR CATALINA HOLDINGS L.P. | LIMITED PARTNER since Oct 2023 | 75% or more | Domestic Entity |
| KKR GROUP CO. INC. Control Indirect owner via KKR GROUP HOLDINGS L.P. | LIMITED PARTNER since Oct 2023 | 75% or more | Domestic Entity |
| KKR GROUP CO. INC. Control Indirect owner via KKR GROUP HOLDINGS CORP. | SHAREHOLDER since Oct 2023 | 75% or more | Domestic Entity |
| KKR GROUP HOLDINGS CORP. Control Indirect owner via KKR GROUP PARTNERSHIP L.P. | GENERAL PARTNER since Oct 2023 | General partner, trustee or manager | Domestic Entity |
| KKR GROUP HOLDINGS CORP. Control Indirect owner via KKR GROUP HOLDINGS L.P. | GENERAL PARTNER since Oct 2023 | General partner, trustee or manager | Domestic Entity |
| KKR GROUP HOLDINGS L.P. Control Indirect owner via KKR GROUP PARTNERSHIP L.P. | LIMITED PARTNER since Oct 2023 | 25–50% | Domestic Entity |
| KKR GROUP PARTNERSHIP L.P. Control Indirect owner via KKR GROUP ASSETS HOLDINGS II L.P. | LIMITED PARTNER since Oct 2023 | 75% or more | Foreign Entity |
| KKR GROUP PARTNERSHIP L.P. Control Indirect owner via KKR GROUP ASSETS GP II LLC | SOLE MEMBER since Oct 2023 | 75% or more | Foreign Entity |
| PETROCHEILOS, GEORGIOS, NMN Control Indirect owner via CATALIO CAPITAL GP, LLC | MEMBER since Jun 2020 | 50–75% | Individual |
| PETROCHEILOS, GEORGIOS, NMN Control Indirect owner via STONEBIRD PARTNERS, LP | MEMBER since Jan 2023 | 50–75% | Individual |
| VOGELSTEIN, RACHEL, JACOB Control Indirect owner via CATALIO CAPITAL GP, LLC | MEMBER since Jun 2020 | 50–75% | Individual |
| VOGELSTEIN, RACHEL, JACOB Control Indirect owner via STONEBIRD PARTNERS, LP | MEMBER since Jan 2023 | 50–75% | Individual |
Ownership & leadership changes · 4 filings with changes since Sep 2, 2020
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedKKR & CO. INC. · SHAREHOLDER · 75% or more · indirect via KKR GROUP CO. INC. · control person
- AddedKKR CATALINA GP LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via KKR CATALINA HOLDINGS L.P. · control person
- AddedKKR CATALINA HOLDINGS L.P. · LIMITED PARTNER · 25–50% · control person
- AddedKKR GROUP ASSETS GP II LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via KKR GROUP ASSETS HOLDINGS II L.P. · control person
- AddedKKR GROUP ASSETS HOLDINGS II L.P. · LIMITED PARTNER · 75% or more · indirect via KKR CATALINA HOLDINGS L.P. · control person
- AddedKKR GROUP ASSETS HOLDINGS II L.P. · SOLE MEMBER · 75% or more · indirect via KKR CATALINA GP LLC · control person
- AddedKKR GROUP CO. INC. · LIMITED PARTNER · 75% or more · indirect via KKR GROUP HOLDINGS L.P. · control person
- AddedKKR GROUP CO. INC. · SHAREHOLDER · 75% or more · indirect via KKR GROUP HOLDINGS CORP. · control person
- AddedKKR GROUP HOLDINGS CORP. · GENERAL PARTNER · General partner, trustee or manager · indirect via KKR GROUP PARTNERSHIP L.P. · control person
- AddedKKR GROUP HOLDINGS CORP. · GENERAL PARTNER · General partner, trustee or manager · indirect via KKR GROUP HOLDINGS L.P. · control person
- AddedKKR GROUP HOLDINGS L.P. · LIMITED PARTNER · 25–50% · indirect via KKR GROUP PARTNERSHIP L.P. · control person
- AddedKKR GROUP PARTNERSHIP L.P. · LIMITED PARTNER · 75% or more · indirect via KKR GROUP ASSETS HOLDINGS II L.P. · control person
- AddedKKR GROUP PARTNERSHIP L.P. · SOLE MEMBER · 75% or more · indirect via KKR GROUP ASSETS GP II LLC · control person
- ChangedCATALIO CAPITAL GP, LLC · ownership 50–75% → Less than 5%
- No longer listedVOGELSTEIN, RACHEL, JACOB · MANAGER OF THE GENERAL PARTNER · 50–75% · control person · listed since Jun 2020
- AddedPETROCHEILOS, GEORGIOS, NMN · MEMBER · 50–75% · indirect via STONEBIRD PARTNERS, LP · control person
- AddedSTONEBIRD PARTNERS, LP · LIMITED PARTNER · 50–75% · control person
- AddedVOGELSTEIN, RACHEL, JACOB · MEMBER · 50–75% · indirect via CATALIO CAPITAL GP, LLC · control person
- AddedVOGELSTEIN, RACHEL, JACOB · MEMBER · 50–75% · indirect via STONEBIRD PARTNERS, LP · control person
- ChangedCATALIO CAPITAL GP, LLC · ownership Less than 5% → 50–75%
- ChangedPETROCHEILOS, GEORGIOS, NMN · indirect via CATALIO CAPITAL GP, LLC: ownership 25–50% → 50–75%
- ChangedPETROCHEILOS, GEORGIOS, NMN · indirect via CATALIO CAPITAL GP, LLC: ownership 50–75% → 25–50%
- ChangedVOGELSTEIN, RACHEL, JACOB · ownership 75% or more → 50–75%
- AddedMALTSEVA, OLGA, EDUARDOVNA · CHIEF COMPLIANCE OFFICER AND HEAD OF OPERATIONS · Less than 5%
- ListedCATALIO CAPITAL GP, LLC · GENERAL PARTNER · Less than 5% · control person
- ListedPETROCHEILOS, GEORGIOS, NMN · MEMBER · 50–75% · indirect via CATALIO CAPITAL GP, LLC · control person
- ListedVOGELSTEIN, RACHEL, JACOB · MANAGER OF THE GENERAL PARTNER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- GILEAD SCIENCES INC$11.2M +48.9%
- SEPTERNA INC$10.9M +153.8%
- NATERA INC$8.1M +57.3%
- HEARTFLOW INC$7.3M +74.2%
- DEFINIUM THERAPEUTICS INC$6.9M +34.9%
Top Trims
- DIANTHUS THERAPEUTICS INC-$43.8M -93.2%
- ULTRAGENYX PHARMACEUTICAL IN-$7.3M -40.8%
- VERADERMICS INC-$5.3M -48.6%
- BRISTOL-MYERS SQUIBB CO-$1.7M -6.7%
- PROTARA THERAPEUTICS INC-$1.0M -34.2%
New Positions
- AVALYN PHARMACEUTICALS INC$55.2M
- JOHNSON & JOHNSON$35.3M
- PARABILIS MEDICINES INC$22.6M
- PROTAGONIST THERAPEUTICS INC$13.1M
- AXSOME THERAPEUTICS INC.$10.6M
Exited Positions
- ASCENDIS PHARMA A/S$29.5M
- TERNS PHARMACEUTICALS INC$21.6M
- SOLENO THERAPEUTICS INC$19.3M
- BOSTON SCIENTIFIC CORP$18.8M
- CYTOKINETICS INC$14.2M
Catalio Capital Management, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $55.2M | 10.37% | 1,675,830 | SH |
| 2 | JOHNSON & JOHNSON | JNJ | 478160104 | $35.3M | 6.63% | 138,946 | SH |
| 3 | GILEAD SCIENCES INC | GILD | 375558103 | $34.0M | 6.39% | 269,309 | SH |
| 4 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $33.9M | 6.37% | 455,041 | SH |
| 5 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $26.6M | 4.99% | 1,215,698 | SH |
| 6 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $26.5M | 4.97% | 562,672 | SH |
| 7 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $23.8M | 4.47% | 412,961 | SH |
| 8 | PARABILIS MEDICINES INC | PBLS | 698955101 | $22.6M | 4.24% | 824,043 | SH |
| 9 | NATERA INC | NTRA | 632307104 | $22.3M | 4.19% | 82,181 | SH |
| 10 | INCYTE CORP | INCY | 45337C102 | $21.7M | 4.08% | 191,627 | SH |
| 11 | SEPTERNA INC | SEPN | 81734D104 | $18.0M | 3.37% | 536,152 | SH |
| 12 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $17.5M | 3.29% | 648,722 | SH |
| 13 | HEARTFLOW INC | HTFL | 42238D107 | $17.1M | 3.21% | 583,055 | SH |
| 14 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $16.1M | 3.03% | 1,080,888 | SH |
| 15 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $14.8M | 2.79% | 276,550 | SH |
| 16 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $13.1M | 2.46% | 106,799 | SH |
| 17 | DISC MEDICINE INC | IRON | 254604101 | $11.7M | 2.19% | 159,384 | SH |
| 18 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $11.3M | 2.12% | 124,778 | SH |
| 19 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $10.6M | 1.99% | 43,182 | SH |
| 20 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $10.6M | 1.98% | 316,252 | SH |
| 21 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $10.3M | 1.94% | 468,750 | SH |
| 22 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $9.2M | 1.73% | 940,855 | SH |
| 23 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $8.6M | 1.61% | 457,839 | SH |
| 24 | ASCENDIS PHARMA A/S | ASND | K08588103 | $8.5M | 1.59% | 31,759 | SH |
| 25 | KARDIGAN INC | KARD | 485925101 | $7.5M | 1.40% | 312,500 | SH |
| 26 | ELEDON PHARMACEUTICALS INC | ELDN | 28617K101 | $6.7M | 1.26% | 1,695,071 | SH |
| 27 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $6.3M | 1.18% | 471,254 | SH |
| 28 | VERADERMICS INC | MANE | 922967104 | $5.6M | 1.06% | 45,856 | SH |
| 29 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $5.4M | 1.02% | 244,929 | SH |
| 30 | FRACTYL HEALTH INC | GUTS | 35168W103 | $4.9M | 0.92% | 6,168,749 | SH |
| 31 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $4.7M | 0.88% | 148,045 | SH |
| 32 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $3.2M | 0.60% | 32,941 | SH |
| 33 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $2.4M | 0.46% | 318,407 | SH |
| 34 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $2.0M | 0.37% | 520,148 | SH |
| 35 | HYPERFINE INC | HYPR | 44916K106 | $1.8M | 0.33% | 1,320,041 | SH |
| 36 | ATAIBECKLEY INC | ATAI | 04650F101 | $1.0M | 0.19% | 196,858 | SH |
| 37 | METAGENOMI THERAPEUTICS INC | MGX | 59102M104 | $629.5K | 0.12% | 528,993 | SH |
| 38 | OUTSET MED INC | OM | 690145206 | $511.0K | 0.10% | 118,279 | SH |
| 39 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $367.9K | 0.07% | 14,718 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $532.1M | 39 | 0001958125-26-000005 |
| 2026-03-31 | 2026-05-15 | $478.7M | 41 | 0001958125-26-000003 |
| 2025-12-31 | 2026-02-17 | $565.8M | 45 | 0001958125-26-000002 |
| 2025-12-31 | 2026-09-02 | $565.8M | 45 | 0001958125-26-000007 |
| 2025-09-30 | 2025-11-14 | $540.9M | 38 | 0001958125-25-000009 |
5TH FLOOR
NEW YORK, NY 10011